tuberculosis-diagnostics-market

Tuberculosis Diagnostics Market By Test Type (Radiographic Methods, Laboratory Methods, Nucleic Acid Testing, Phage Assay, Cytokine Detection Test, Detection Of Drug Resistance, Mantoux Test) - Growth, Future Prospects, And Competitive Analysis, 2024 -2032

18 Jul 2017 Format PDF icon PPT icon XLS icon Request Sample

This report on global tuberculosis diagnostics market studies various tuberculosis diagnostics test type. Healthcare regulatory agencies such as WHO, CDC are taking initiatives towards global awareness of tuberculosis and improvising the diagnostic methods. Large patient pool suffering with tuberculosis, rising public awareness regarding tuberculosis and early diagnosis and technological advancement in the testing methods such as Mantoux test, and Cytokine detection test are the driving factors for the tuberculosis diagnostics market.

The global tuberculosis diagnostics market is growing at a CAGR of 4.5% during the forecast period from 2023 to 2030. Tuberculosis accounts for a large share of the global infectious disease burden, resulting in about 9.6 million new cases and 1.5 million deaths per year. Tuberculosis is highly prevalent in under developed parts of the world affecting millions of lives, especially in Asia and Africa. Curently, tuberculosis has also developed into more diverse and potent forms that are referred as multi-drug resistant (MDR) or extensively drug resistant (XDR) tubercuolsis. These conditions are also spreading at a rapid rate and require extensive diagnostic and treatment measures to check its spread globally. According to World Health Organization (WHO) in 0.49 million new cases of MDR tuberculosis was recorded in 2016, and 47% of these cases were from China, India and Russia. 

Continuous and effective control measures and programs carried out by WHO and other global health organizations such as Stop TB and DOTS (Directly Observed Treatment, Short-course) most developed nations have been able to minimize the spread of this disease. Various tuberculosis diagnostics tests are available in the global market for early and accurate diagnosis of the disease, thus ensuring proper treatment of the affected patient population. Some of the major commercially available tuberculosis diagnostic tests include nucleic acid tests, culture tests, tuberculin skin tests, chest X-ray, sputum smear microscopy, and drug susceptibility testing. The latest next-generation Xpert MTB/RIF Ultra diagnostic test by Cephied, Inc., has shown significant sensitivity in detection of Mycobacterium tuberculosis and is recommended by WHO.

The major players operating in the market include Alere, Inc., Abbott Laboratories, Thermo Fisher Scientific Corporation, Becton Dickinson and Company, BioMerieux Company and Cephied, Inc., among others.

Detection of drug resistance is projected to exhibit fastest growth rate

Tuberculosis is one of the leading cause of death worldwide, according to the World Health Organization in 2013 around 9 million new cases of tuberculosis were reported with approximately 1.5 million deaths. The tuberculosis diagnostic market segment is driven by factors such as increasing diagnosis rate in the high prevalence regions, advanced technologies such as radiographic methods and cytokine detection test, cost efficient diagnostic tests are in demand and launching of technologically advanced diagnostic kits.

In 2021 laboratory diagnostics held the largest market share in the test type segment chiefly due to factors such as rising prevalence of tuberculosis they are affordable and very easy to perform. The restraints of the laboratory diagnostic test are compromised accuracy and the long incubation period required for the interpretation of diagnosis. Nucleic acid test and Mantoux test will be the fastest growing market throughout the forecast period due to key market drivers such as advanced techniques, less incubation period required for interpretation of the diagnosis performed, and high accuracy. The major players involved the manufacturing of the diagnostic kits and equipment are Alere, Inc. Abbott Laboratories, Inc., Thermo Fisher Scientific Inc., Becton Dickinson and Company, F.Hoffman La Roche AG, Qiagen, BioMerieux SA, Cephied, Inc., Epistem plc., Hain Lifescience GmbH and Hologic Corporation.

Asia Pacific is expected to witness the highest CAGR of 5.5%

North America will be the fastest-growing market for tuberculosis diagnostics throughout the forecast period 2023-2030. According to the Centers for Disease Control and Prevention, approximately 9,557 new cases of TB were reported in 2015, the market growth is mainly attributed to rising public awareness of tuberculosis leading to early diagnosis, evolved reimbursement scenario, and developed healthcare infrastructure. According to the World Health Organization (WHO) in 2015, 323,000 new TB cases were reported in Europe i.e. approximately 900 people suffered with TB each day. Europe is expected to be the second largest market due to rising prevalence of MDR-TB, government & non-government organizations grants to strengthen R&D facilities to launch novel tuberculosis diagnostics testing kits, and supportive regulatory approval for tuberculosis diagnostics market.

In base year 2021, Asia Pacific was observed as the leading market for tuberculosis diagnostics due to factors such as rising prevalence of tuberculosis, according to World Health Organization in South East Asia annually 2 million people are diagnosed with TB, competitive market due to manufactures involved in tuberculosis diagnostic kit production, increasing disposable income in these regions and government and non-government initiatives to mitigate tuberculosis as per TB programmes. However, factors such as developing health infrastructure, increasing awareness about tuberculosis diagnostics are going to fuel the rapid growth of tuberculosis diagnostics market in Latin America and Middle East and Africa region in the near future.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Tuberculosis Diagnostics market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Tuberculosis Diagnostics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
Segmentation
Test
  • Radiographic Methods
  • Laboratory Methods
    •     Smear Microscopy
    •     Culture Based Test
  • Nucleic Acid Testing
  • Phage Assay
  • Cytokine Detection Test
  • Detection of Drug Resistance
  • Mantoux Test

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Tuberculosis Diagnostics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Tuberculosis Diagnostics market?
  • Which is the largest regional market for Tuberculosis Diagnostics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Tuberculosis Diagnostics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Tuberculosis Diagnostics market worldwide?
Choose Licence Type
$4500
$6500
$9000
Why Acute
View Other Reports